Acute respiratory distress syndrome Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Acute respiratory distress syndrome market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma

[Nevada, United States] - DelveInsight's "Acute respiratory distress syndrome Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Acute respiratory distress syndrome, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Acute respiratory distress syndrome Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Acute respiratory distress syndrome Market Report:
• The Acute respiratory distress syndrome market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: BioAegis Therapeutics Inc. announced that BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections.
• In October, 2024: Dompé Farmaceutici S.p.A announced that a Phase 2, randomized, double-blinded, placebo controlled, multicenter study. All patients will receive therapy in line with current standard-of-care as it pertains to ARDS management (protocolized ventilator management will be made available to all sites in accordance with currently accepted standard of care). Patients will be randomized (1:1) to either reparixin or placebo.
• In September, 2024: AstraZeneca announced that the purpose of their study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
• In August, 2024: MediciNova announced that their study aims to evaluate MN-166 (ibudilast) in patients with COVID-19 who are at risk of developing acute respiratory distress syndrome. Subjects will be screened, randomly assigned to MN-166 or placebo groups, receive study drug on Days 1-7, and followed up on Day 14 and Day 28.
• Among the 7MM, the US had the highest incident of ARDS with approximately 574,259 cases, in 2022, followed by Germany.
• According to DelveInsight's estimates, the total incident population of ARDS, in the 7MM, was estimated to be approximately 956,568 cases, in 2022. These cases are projected to increase during the forecast period (2023-2034).
• According to DelveInsight's estimates, in 2022,Japan had approximately 43,054total incidentcases of ARDS, of which nearly30%were mild,47% were moderate, while23%was severe.
• Key Acute respiratory distress syndrome Companies are as follows: Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma
• Key Acute respiratory distress syndrome Therapies are as follow: EB05 (paridiprubart), Alteplase (Actilyse), BIO-11006, ExoFlo (DB-001), STSA-1002, HCR040, GEn-1124, MultiStem, recombinant, Alteplase, Veru-111, Rhu-pGSN, ALT-100 mAb, agenT-797, ALT-836, Interferon Beta
• Launching multiple stage Acute respiratory distress syndrome pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Acute respiratory distress syndrome market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Acute respiratory distress syndrome Overview:
ARDS is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked byleakage of fluid into the lungs, making breathing difficult or impossible. It is a severe lung condition that causes lowblood oxygen. People who develop ARDS are usually ill due to another disease or a major injury which leads to fluidbuild-up inside the tiny air sacs of the lungs, and surfactant breakdown.

Acute respiratory distress syndrome Epidemiology Segmentation:
The Acute respiratory distress syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Acute respiratory distress syndrome Total Incident Cases
• Acute respiratory distress syndrome Severity-specific Cases
• Acute respiratory distress syndrome Incident Cases

For more information about Acute respiratory distress syndrome companies working in the treatment market, visit https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Acute respiratory distress syndrome Market Insights
Treatment of acute respiratory distress syndrome is supportive and includes mechanical ventilation,prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities. Despite decades of research, treatment options for ARDS are restricted.Supportive care with mechanical ventilation remains the mainstay of management.

Acute respiratory distress syndrome Drugs Uptake
• EB05 (paridiprubart) is an experimental monoclonal antibody that Edesa believes could regulate the overactive anddysfunctional immune response associated with ARDS. Specifically, the drug inhibits toll-like receptor 4 (TLR4)signaling which is an important mediator of inflammation responsible for acute lung injury that is activated bySARS-CoV2, SARS-CoV1, and influenza viruses.
• ExoFlo (DB-001) being developed by Direct Biologics is an extracellular signal product isolated from human bonemarrow mesenchymal stem or stromal cells (BM-MSCs) that contains growth factors and extracellular vesiclesincluding exosomes.
• MultiStem (HLCM051), a patented regenerative product, which can promote tissue repair and healing in a varietyof ways, such as through the production of multiple therapeutic factors produced in response to signals ofinflammation and tissue damage and restore immune system balance, is being developed for ARDS
• Remestemcel-L being developed by Mesoblast is an investigational therapy comprising cultureexpanded MSCs derived from the bone marrow of an unrelated donor and is administered in a series ofintravenous infusions
• TP508, being developed by Chrysalis BioTherapeutics, is a GMP manufactured 23 amino acid peptidethat represents a natural region of human thrombin that is released at the site of injury to initiate tissuerevascularization, regeneration and repair

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Acute respiratory distress syndrome Therapies and Key Companies:
• EB05 (paridiprubart): Edesa Biotech/Light Chain Biosciences
• Alteplase (Actilyse): Boehringer Ingelheim/ Genentech
• BIO-11006: BioMarck Pharmaceuticals
• ExoFlo (DB-001): Direct Biologics
• STSA-1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd
• HCR040: Histocell, S.L.
• GEn-1124: GEn1E Lifesciences
• MultiStem: Healios K.K.
• recombinant: Suntory Pharmaceutical
• Alteplase: Boehringer Ingelheim
• Veru-111: Veru Inc.
• Rhu-pGSN: BioAegis Therapeutics Inc.
• ALT-100 mAb: Aqualung Therapeutics Corp
• agenT-797: MiNK Therapeutics
• ALT-836: Altor BioScience
• Interferon Beta: Faron Pharmaceuticals Ltd

Acute respiratory distress syndrome Epidemiology:
Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening lung condition that arises from various causes such as pneumonia, sepsis, trauma, and COVID-19. It results in the rapid onset of widespread inflammation in the lungs and leads to respiratory failure. ARDS occurs in approximately 10% of all ICU admissions and affects around 200,000 individuals per year in the U.S. alone. Globally, the incidence is about 1 to 8 per 100,000 population annually. Key risk factors include sepsis, trauma, aspiration, pneumonia, and viral infections (e.g., COVID-19), with sepsis accounting for approximately 40-50% of ARDS cases.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Acute respiratory distress syndrome Market Drivers:
• Advances in Ventilator Technologies
• Focus on Novel Therapeutics
• Government and Regulatory Support
• Biomarker Development for Early Detection

Acute respiratory distress syndrome Market Barriers:
• Lack of Targeted Therapies
• High Mortality and Complication Rates
• Cost of Advanced Treatments
• Regulatory and Clinical Trial Challenges

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Acute respiratory distress syndrome Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Acute respiratory distress syndrome Companies: Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma
• Key Acute respiratory distress syndrome Therapies: EB05 (paridiprubart), Alteplase (Actilyse), BIO-11006, ExoFlo (DB-001), STSA-1002, HCR040, GEn-1124, MultiStem, recombinant, Alteplase, Veru-111, Rhu-pGSN, ALT-100 mAb, agenT-797, ALT-836, Interferon Beta
• Acute respiratory distress syndrome Therapeutic Assessment: Current marketed and emerging therapies
• Acute respiratory distress syndrome Market Dynamics: Acute respiratory distress syndrome Market drivers and Acute respiratory distress syndrome barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acute respiratory distress syndrome Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Acute respiratory distress syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Acute Respiratory Distress Syndrome Market Overview at a Glance
4 Methodology of Acute Respiratory Distress Syndrome Epidemiology and Market
5 Executive Summary of Acute Respiratory Distress Syndrome
6 Key Events
7 Disease Background and Overview
8 Patient Journey
9 Epidemiology and Patient Population
10 Emerging Drugs
12 Acute Respiratory Distress Syndrome: Market Analysis
13 Key Opinion Leaders' Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.